Thursday, October 20, 2011
Famy Care settles Femcon Fe lawsuit
Famy Care, a Mumbai-based women healthcare speciality company, jointly with global generic company Mylan Inc. has entered into a settlement agreement with Warner Chilcott resolving ongoing paragraph IV lawsuit related to Femcon Fe chewable tablets, an oral low-dose (28-days) contraceptive regimen of 21 active chewable tablets of norethindrone and ethinyl estradiol (EE) combination followed by 7 ferrous fumarate (placebo) chewable tablets. As per settlement, the ongoing litigation has been dismissed and Mylan may market generic Femcon Fe soon after receipt of final approval from the US Food and Drug Administration.

Pune-based Lupin lately launched the authorized generic of Femcon Fe following last year settlement agreement with Warner Chilcott that granted a non-exclusive license to OB-listed US Patent No. 6,667,050. In 2008 and 2009, Warner resolved Femcon Fe paragraph IV lawsuits and entered into settlement agreements with Barr (now Teva Pharmaceutical) and Watson. Mylan will now be fourth company to enter depleting generic Femcon Fe market before the expiration of OB patent in April 2019.

1 Comments:

At 12:00 PM , Blogger kavin hill said...
As per settlement, the ongoing litigation has been dismissed and Mylan may market generic Femcon Fe soon after receipt of final approval from the US Food and Drug Administration.

tantrik  

Post a Comment

Subscribe to Post Comments [Atom]

<< Home